IL-22 and IL-22 Receptors {#Sec1}
=========================

IL-22 was originally cloned from IL-9-treated mouse T cells in 2000 and named IL-TIF (IL-10 related T-cell-derived inducible factor) (Dumoutier et al. [@CR32]). The human orthologue was subsequently identified with 79 % identity to mouse IL-22 and 25 % identity to human IL-10 (Dumoutier et al. [@CR34]; Xie et al. [@CR167]). Because of the weak but significant homology with IL-10, IL-22 was classified as a member in the IL-10 cytokine family, along with IL-10, IL-19, IL-20, IL-24, IL-26, IL-28A, IL-28B, and IL-29 (Ouyang et al. [@CR103]). Cytokines from the IL-10 family share 20--30 % amino acid identity and also a weaker homology with cytokines in the interferon (IFN) family. Together, IL-10 and IFN cytokine families form the class II cytokine superfamily.

Gene and Structure of IL-22 {#Sec2}
---------------------------

The human IL-22 gene consists of five introns and six exons and is located on chromosome 12q15, adjacent to genes of IFN-γ and IL-26. The isolated cDNA encodes a 179-amino-acid-long protein with a 33-amino-acid signal peptide (Dumoutier et al. [@CR33]). Sharing structural similarity with other IL-10 family members, IL-22 contains six α-helices (A--F), forming a bundle structure with a compact hydrophobic core inside (Fig. [6.1a](#Fig1){ref-type="fig"}). In contrast to IL-10, which forms an intertwined dimer for receptor binding, IL-22 is a monomer (Nagem et al. [@CR96]). IL-22 is heavily glycosylated with three N-linked glycosylation sites (Asn-X-Ser/Thr) at asparagines (Asn) -54, -68 and -97) (Fig. [6.1a](#Fig1){ref-type="fig"}) (Xu et al. [@CR169]). However, the biological function of IL-22 is not fully dependent on glycosylation. The *Escherichia coli-derived* protein has normal biological activity without glycosylation. In fact, comparison of the IL-22 structures purified from *Drosophila* and *E. coli* reveals that the glycosylation only causes minor structural changes (Xu et al. [@CR170]). There are four cysteines within IL-22 to create two disulfide linkages (Cys40--Cys130, Cys89--Cys178). The first disulfide bond holds together the N-terminal coil and the DE loop, and the second disulfide bond stabilizes the N-terminus of helix C and the C-terminus of helix F (Fig. [6.1a](#Fig1){ref-type="fig"}) (Nagem et al. [@CR96]). Fig. 6.1Structure of human interleukin (IL)-22 and IL-22R1. **(a)** Crystalline structure of IL-22 from IL-22--IL-22R1 complex (Protein Data Bank ID code 3DGC). Six helices (*A--F*) are colored from the N-terminus (*blue*) to C-terminus (*red*). Three glycosylation sites (N54, N68, N97) are labeled with *arrowed lines*. Two disulfide bonds (C40--C132, C89--C178) are shown with *blue double-arrow lines*. **(b)** Complex of IL-22--IL-22R1. IL-22R1 (*dark grey*) contains D1 and D2 domains. Critical amino acids for IL-22R1 and IL-10R2 binding on IL-22 are labeled

IL-22 interacts with the heterodimeric membrane-spanning receptor complex, IL-22R1 (also known as IL-22Ra1, CRF2-9, and zcytor11), and IL-10R2. Both subunits belong to the class II cytokine receptor or interferon receptor family with signature fibronectin type III domains (Ouyang et al. [@CR103]). The gene of IL-22R1 is located on chromosome 1 and encodes a 574-amino-acid protein that contains an extracellular ligand-binding domain, a membrane-spanning helix, and an intracellular domain (Xie et al. [@CR167]). *Il-10r2* is located on chromosome 21 and shares a similar organization with a much shorter cytoplasmic tail (Kotenko et al. [@CR72]). IL-10R2 is a shared common receptor chain for several other IL-10 family cytokines including IL-10, IL-26, IL-28A, IL-28B, and IL-29 (Ouyang et al. [@CR103]). The finding of receptor sharing within the same family is not uncommon, as the common γ-chain is shared by multiple cytokines. Similarly, IL-22R1 can also pair with IL-20R2 to engage the binding of IL-20 and IL-24. Although IL-10R2 is ubiquitously expressed, IL-22R1 is primarily detected on cells with epithelial origin.

Receptor Binding {#Sec3}
----------------

As a monomer, IL-22 can form a 1:1 complex with the soluble IL-22R1 extracellular domain in solution. The two tandem fibronectin domains (D1 and D2) of IL-22R1 rotate to an angle to form an L-shape, where the interface comes in contact with IL-22 residues on helix A, the AB loop, and helix F (Fig. [6.1b](#Fig1){ref-type="fig"}). Several residues that are critical for IL-22R1 binding are located in helix F (Lys-162, Glu-166, Met-172, Arg-175) and the AB loop (Thr-70), and create either hydrogen bonds or van der Waals interactions between IL-22 and IL-22R1 (Jones et al. [@CR60]). The specific residues in contact surfaces ensure the specificity between IL-22-IL-22R1 interactions and are distinct from other cytokine--receptor complexes in the family. IL-10R2 comes in contact with IL-22/IL-22R1 complex at three distinct surface sites. Helices A and B in IL-22 are predominantly engaged in binding to two of three sites on IL-10R2 whereas the third site interacts with IL-22R1. In contrast to IL-22R1-binding sites where most of the residues locate toward the C-terminus of IL-22, IL-10R2-binding spots on IL-22 are mainly located on the N-terminal end of the helix, including residues Tyr-51, Asn-54, Arg-55, Tyr-114, and Glu-117 (Fig. [6.1b](#Fig1){ref-type="fig"}) (Logsdon et al. [@CR82]). The formation of the IL-22--IL-22R1--IL-10R2 complex is sequential. Surface plasmon resonance studies revealed high-affinity binding of IL-22 to IL-22R1 (20 nM) but very weak affinity (120 μM) to IL-10R2 (Logsdon et al. [@CR82]). In fact, IL-10R2 displays a diminished affinity to IL-22 with a substantially increased affinity to the IL-22/IL--22R1 complex (Logsdon et al. [@CR81]).

IL-22-Binding Protein {#Sec4}
---------------------

A protein that shares 34 % sequence identity with the extracellular region of IL-22R1 was discovered by screening genomic DNA databases and named IL-22-binding protein (IL-22BP, also known as IL-22Ra2, CRF2-10, CRF2-s1, and ZcytoR16). IL-22BP lacks transmembrane and intracellular domains and functions as a naturally occurring IL-22 antagonist (Gruenberg et al. [@CR44]; Kotenko et al. [@CR73]; Logsdon et al. [@CR81]; Weiss et al. [@CR160]; Xu et al. [@CR168]). Soluble receptors or membrane-bound decoy receptors that serve as negative regulators for cytokines have previously been found for other cytokines, such as IL-1 and IL-18, but IL-22BP is the only naturally expressed soluble receptor discovered in the class II cytokine receptor family. IL-22BP is encoded by a distinct gene on chromosome 6, in a proximal distance of the class II cytokine receptor cluster containing Il-20r1 and ifngr1. Although IL-22BP shares weaker homology with other receptors of the IL-10 family cytokine such as IL-10R1 (29 %), it only specifically blocks IL-22 signaling. IL-22BP is expressed in a wide range of tissues including lymphoid and nonlymphoid tissues with three mRNA variants produced by alternative splicing, and the variant-2 with 231 amino acids neutralizes IL-22 activity. IL-22BP structurally resembles IL-22R1 with two disulfide bonds stabilizing D1 and D2 domains, and the interaction interface to IL-22 is located within IL-22 helix A, the AB loop, and helix F. In contrast to IL-22R1, IL-22BP forms five completely different salt bridges or hydrogen bonds, and a hydrophobic cluster with Phe-57, Phe-171, and Met-172 on IL-22. The binding affinity of IL-22BP to IL-22 (\~1 pM) is significantly higher than IL-22--IL-22R1 (\~nM), illuminating the tight regulation of IL-22BP on IL-22 activity (Jones et al. [@CR60]).

Signal Transduction {#Sec5}
-------------------

Upon binding to the receptor complex, IL-22 activates Janus Kinase (Jak) and Signal Transducer and Activator of Transcription (Stat) signaling pathways, particularly, phosphorylation of tyrosine kinases Jak1 and Tyk2 (Fig. [6.2](#Fig2){ref-type="fig"}). Subsequently, transcription factor Stat3 is activated, and in some cells phosphorylation of Stat1 and Stat5 may also occur (Dumoutier et al. [@CR32], [@CR35]; Lejeune et al. [@CR76]; Xie et al. [@CR167]). A serine residue of Stat3 (Ser 727) can be phosphorylated by IL-22 stimulation, and this serine phosphorylation is required to achieve maximal transactivation (Lejeune et al. [@CR76]). In the intracellular tail of the IL-22R1 chain, there are in total eight tyrosine residues that can be phosphorylated by activated Jak1 or Tyk2 and serve as potential docking sites for Stat molecules upon IL-22 stimulation. Interestingly, although these Tyr residuals are necessary for the binding of Stat5 and Stat1 to IL-22R1, they are dispensable for Stat3 activation (Dumoutier et al. [@CR36]). Instead, the coiled-coil domain of Stat3 can bind directly to the C-terminal tail of the IL-22R1 chain (Fig. [6.2](#Fig2){ref-type="fig"}). The biological significant of this finding is unclear at present. In vivo, Stat3 is directly activated by IL-22 in epithelia and is necessary in mediating the downstream biological effects of IL-22 (Pickert et al. [@CR112]; Sugimoto et al. [@CR139]; Zheng et al. [@CR179]). In addition to Stat molecules, IL-22 is able to activate key kinases MEK1/2, ERK1/2, JNK, and p38 of MAP kinase pathways, as well as Akt, SOCS-3, and transcription factors NF-κB and AP-1 in different cell types (Andoh et al. [@CR3]; Brand et al. [@CR14]). Fig. 6.2IL-22 binds to receptors and activates downstream signaling transduction. The engagement of IL-22 to the IL-22R1--IL-10R2 complex activates Jak/Stat pathways and primarily signals through Stat3. IL-22R can associate with Stat3 in a tyrosine-independent manner. Stat1, Stat5, and MAP kinase pathways can be activated under certain conditions. *BP*, binding protein

Cellular Sources and Regulation of IL-22 {#Sec6}
========================================

IL-22 is broadly expressed by many types of leukocytes, including CD4^+^ T cells, CD8^+^ T cells, and γδ T cells, as well as various innate lymphocytes (ILCs) (Fig. [6.3](#Fig3){ref-type="fig"}) (Ouyang et al. [@CR103]; Rutz and Ouyang [@CR122]). Given the essential roles of IL-22 in tissue protection under various homeostatic, infectious, and inflammatory states as discussed herein, these different cellular sources are not redundant for the biological functions of IL-22 in vivo. Especially, the activation signals required for IL-22 production in these cells and homing properties of these cells into different organs are all different. Fig. 6.3Various cell types produce IL-22. **(a)** T-cell subsets secrete IL-22 under different stimulations. CD4 T cells are major producers and are categorized into Th17 and Th22 subgroups based on their cytokine profiles. **(b)** Innate lymphocytes (ILCs) are innate sources of IL-22. LTi-like and NK-like ILCs, although defined with different surface markers, are able to produce IL-22 under similar conditions

CD4 T Helper Cells {#Sec7}
------------------

IL-22 was originally identified as a cytokine produced from activated murine CD4^+^ T cells and human T cells (Dumoutier et al. [@CR32], [@CR34]; Wolk et al. [@CR162]). In various CD4^+^ T helper cell subsets, Th1 cells produce a higher level of IL-22 whereas Th2 cells express a very low, but detectable, level of IL-22 (Gurney [@CR45]; Wolk et al. [@CR162]). A new T helper subset, Th17 cells, was described in 2005 (Harrington et al. [@CR47]; Park et al. [@CR107]). Th17 cells, which primarily express the signature cytokine IL-17, are critical mediators of pathogenesis of inflammatory disorders and antibacterial host defense (Ouyang et al. [@CR102]). Shortly after the discovery of Th17 cells, IL-22 was identified as another functionally important cytokine that helped to define this T helper lineage (Chung et al. [@CR22]; Liang et al. [@CR78]; Zheng et al. [@CR179]). IL-22 production from Th17 cells is significantly higher than that from Th1 cells. Transforming growth factor (TGF)-β and IL-6 are necessary and sufficient to induce Th17 cell differentiation from naïve CD4^+^ T cells (Bettelli et al. [@CR9]; Mangan et al. [@CR85]; Veldhoen et al. [@CR151]). Surprisingly, we noticed three different 'flavors' of Th17 cells depending on the concentration of TGF-β present in the culture (Fig. [6.3a](#Fig3){ref-type="fig"}) (Zheng et al. [@CR179]). With a high dose of TGF-β, T cells produce only IL-17 but not much IL-22. These IL-17-only-producing T cells have been identified in human ulcerative colitis (UC) patients, and their presence is correlated with active inflammation in the intestine (Broadhurst et al. [@CR16]). A small amount of TGF-β in combination with IL-6 can promote Th17 cells producing both IL-17 and IL-22. IL-6 alone without addition of TGF-β is not able to induce IL-17 production from T cells. Under this condition, however, T cells produce the highest level of IL-22, suggesting TGF-β is differentially required for IL-17 and IL-22 regulation. The IL-22-only-producing CD4^+^ T helper cells were discovered in human peripheral blood mononuclear cells (PBMC) and are named Th22 cells (Duhen et al. [@CR31]; Eyerich et al. [@CR39]; Trifari et al. [@CR146]). The Th22 cells not only express CCR6, a cell-surface marker for Th17 cells, but also the skin-homing receptors CCR4 and CCR10. Consistently, Th22 cells were found in epidermis of human inflammatory skin disorders, and expressed genes involved in tissue remodeling, suggesting an important role in skin homeostasis. Additional to αβ CD4^+^ T cells, both CD8^+^ T cells and γδ T cells produce IL-22 under the stimulation of IL-23 (Fig. [6.3a](#Fig3){ref-type="fig"}) (Billerbeck et al. [@CR10]; Ciric et al. [@CR23]; Martin et al. [@CR86]; Sutton et al. [@CR141]; Zheng et al. [@CR179]). Mouse unconventional γδ T cells were found to coexpress IL-22 with IL-17 and IL-21 in response to IL-23 and IL-1β without T-cell-receptor engagement (Billerbeck et al. [@CR10]; Ciric et al. [@CR23]; Martin et al. [@CR86]; Sutton et al. [@CR141]). These cells express CCR6, orphan nuclear receptor RORγt, aryl hydrocarbon receptor (AHR), IL-23R, and receptors for pathogen products, and mediate antibacterial host defense and pathogenesis of experimental autoimmune encephalomyelitis (EAE), a murine model for multiple sclerosis (MS). Invariant natural killer (NK) T cells, another unconventional T-cell type that express both NK and T-cell markers, are capable of releasing IL-22 upon T-cell receptor (TCR) stimulation and protecting liver from inflammatory damage in a murine acute hepatitis model (Goto et al. [@CR43]; Wahl et al. [@CR154]).

Innate Lymphocytes {#Sec8}
------------------

NK cells in human PBMC were reported to express a low level of IL-22, suggesting that IL-22 may also be produced by innate leukocytes (Wolk et al. [@CR162]). Indeed, the induction of IL-22 in the colon with *Citrobactor rodentium* infection remained intact in Rag2-deficient mice, supporting a non-T-cell source of IL-22 (Zheng et al. [@CR180]). A NK-like ILC subset was subsequently discovered by several groups as one of the major innate sources of IL-22 (Fig. [6.3b](#Fig3){ref-type="fig"}) (Cella et al. [@CR20]; Satoh-Takayama et al. [@CR125]). The NK-like cells express NK-specific marker NKp46 and an intermediate level of NK1.1, but have low or no expression of stimulatory or inhibitory NK receptors and possess no effector function of NK cells. Moreover, these cells express CD117, CD127, and a high level of RORγt. Developmentally, NKp46^+^CD3^−^ cells are dependent on RORγt, but not IL-15, which is required for NK cells. They produce abundant IL-22 but little IL-17 in response to commensal microbiota. A similar IL-22-producing counterpart was identified from human mucosa-associated lymphoid tissues such as the tonsil and Peyer's patches (Cella et al. [@CR20]). Instead of NKp46, the human cells express NKp44, as well as CD56 and CD127 (Cupedo et al. [@CR26]). The NKp44^+^ cells were named NK-22 because of their ability to produce IL-22 and respond to IL-23. These NK-22 cells are important sources of IL-22 and regulate the epithelial host defense mechanism and maintenance of dynamic equilibrium between microbial flora and immune surveillance. It is noteworthy that IL-22-producing NK-like ILCs are not only associated with mucosal tissues and restricted to NKp46 expression but are also identified in other organs such as skin dermis, suggesting they may broadly participate in host defense through IL-22 production (Dhiman et al. [@CR28]; Hughes et al. [@CR54]; Satoh-Takayama et al. [@CR126]).

In parallel, a previously defined ILC subset, lymphoid tissue inducer (LTi) cells, was noticed to be able to produce IL-22 upon IL-23 stimulation (Fig. [6.3b](#Fig3){ref-type="fig"}) (Takatori et al. [@CR143]). Splenocytes from Rag2^−/−^ mice that are lacking both T and NK T cells still produce a large amount of IL-22 in reaction to IL-23, whereas in Rag2^−/−^ common γ^−/−^ splenocytes, IL-22 production is completely abrogated. A group of LTi-like cells, which express CCR6, RORγt, AHR, and IL-23R, are identified as the sources of IL-22 (Takatori et al. [@CR143]; Veldhoen et al. [@CR152]). LTi is essential for the formation of secondary lymphoid organs during embryogenesis (Mebius [@CR89]). Both inhibitor of differentiation 2 (Id2) and RORγt are required for LTi development (Sun et al. [@CR140]; Yokota et al. [@CR174]). The LTi cells phenotypically lack surface markers for T cells, B cells, and myeloid cells, but express lymphotoxin-α (LT-α), LT-β, several chemokine receptors, and cytokine receptors including CD127 and CD117. Additionally, LTi cells express CD4 in the mouse (Spits and Di Santo [@CR135]). Because LTi-like cells are able to secrete IL-22 upon activation and preferentially reside in mucosal-associated lymphoid tissues, they may play essential functions in maintaining mucosal homeostasis (Cupedo et al. [@CR26]; Takatori et al. [@CR143]).

A study suggested that LTi-like cells but not the NK-like cells were the major sources of IL-22 during *C. rodentium* infection in the colon (Sonnenberg et al. [@CR133]). However, given many common features shared by LTi-like cells and NK-like ILCs, these cells may belong to the same ILC group with slight differences in the expression of certain cell-surface markers. The connection between LTi-like and NK-like cells has been built not only on their functions but also in lineage development (Sawa et al. [@CR128]). The LTi-like cells could upregulate NK cell-surface marker CD56 and acquire a low level of cytolytic activity when culturing under conditions favoring NK cell differentiation (Crellin et al. [@CR25]; Cupedo et al. [@CR26]). Despite a suggestion that NK-like IL22^+^ cells may come from IL-1β-stimulated immature NK cells, both LTi-like and NK-like IL-22-producing cells remain their RORc expression throughout the culture and represent a stable RORc^+^ lineage that is functionally and developmentally distinct from conventional NK cells (Crellin et al. [@CR25]; Hughes et al. [@CR54], [@CR55]; Satoh-Takayama et al. [@CR127]). Although initially IL-22-producing ILCs have been given different names by different groups, such as NK-22, NCR22, and ILC-22, the nomenclature has been made uniform and all IL-22-producing ILCs are grouped into group 3 ILCs (Fig. [6.3b](#Fig3){ref-type="fig"}) (Spits et al. [@CR136]).

Regulation {#Sec9}
----------

Similar to other cytokines, the production of IL-22 from leukocytes is tightly controlled (Ouyang et al. [@CR103]; Rutz and Ouyang [@CR122]). The regulation of IL-22 is best studied in CD4^+^ T helper cells. Because L-22 is a signature cytokine of Th17 cells, many pathways and factors that are essential for Th17 cell development and IL-17 production also control the expression of IL-22 (Korn et al. [@CR71]; Ouyang et al. [@CR102]). IL-6, IL-21, and IL-23 can all activate Stat3 in T cells. All three cytokines play critical roles in regulation of Th17 development and IL-17 and IL-22 production. The downstream transcription factor Stat3 thus also has an indispensable function in induction of both IL-17 and IL-22 from T cells (Yang et al. [@CR172]). Other pro-inflammatory cytokines including IL-1β and tumor necrosis factor (TNF)-α can augment IL-17 and IL-22 expression. As discussed earlier, IL-23 not only induces IL-22 production from T-cell subsets but also is indispensable for IL-22 expression from ILCs, especially in vivo (Zheng et al. [@CR179], [@CR180]). The orphan nuclear receptors RORc in human, RORγt, and RORα in mouse are considered as master transcription factors for Th17 lineage formation, and these factors also participate in regulation of IL-22 production in Th17 cells (Ivanov et al. [@CR58]; Volpe et al. [@CR153]; Yang et al. [@CR173]). The AHR, a ligand-dependent transcription factor sensing xenobiotic metabolites, promotes Th17 cell differentiation and drives IL-22 expression (Quintana et al. [@CR117]; Veldhoen et al. [@CR152]). AHR ligand stimulation of human PBMC strongly upregulates IL-22 production in Th17 cells, and Notch signaling enhances IL-22 secretion indirectly through activating the AHR (Alam et al. [@CR2]; Brembilla et al. [@CR15]; Ramirez et al. [@CR119]).

Several pathways, including TGF-β, inducible costimulator (ICOS), and IL-27, negatively regulate IL-22 production in T cells (Liu and Rohowsky-Kochan [@CR80]; Paulos et al. [@CR109]; Rutz et al. [@CR123]; Volpe et al. [@CR153]; Zheng et al. [@CR179]). We recently identified c-Maf as a potential downstream transcription repressor that mediated the suppression of IL-22 in T cells by TGF-β. Because TGF-β is required for IL-17 induction in T cells, it controls the balance of IL-17 and IL-22 in T cells. IL-22 shares similar biological functions with IL-17 for induction of antimicrobial responses, chemokines, and other pro-inflammatory genes from epithelial cells. During pathogen invasion, coexpression of IL-22 and IL-17 may enhance the host defense mechanism through the synergistic effects of both cytokines (Aujla et al. [@CR4]). Consistently, in inflammatory diseases such as psoriasis and rheumatoid arthritis, Th17 cells coexpress IL-17 and IL-22 in inflamed tissues and may contribute to the pathogenesis (Pene et al. [@CR111]). On the other hand, IL-22 has strong tissue-protective functions (Zenewicz et al. [@CR177]; Zheng et al. [@CR179]). As discussed herein, IL-22-only-producing Th22 cells may have distinct biological roles from Th17 cells in both infectious and autoimmune diseases.

Biological Functions of IL-22 {#Sec10}
=============================

Carrying the name of "interleukin," IL-22 was first searched within the lymphopoietic system for its biological function. However, from freshly isolated human monocytes, T cells, NK cells, and B cells, there was no detectable IL-22R1 expression even with activation (Wolk et al. [@CR163]). Consistently, IL-22 induced neither any cytokine production from PBMC nor upregulation of activation markers. IL-22 is secreted by various leukocyte subsets, whereas the expression of IL-22R1 is restricted to epithelial cells and the cells originated from epithelium (Aggarwal et al. [@CR1]; Dumoutier et al. [@CR34]). Therefore, IL-22 is a key cytokine to mediate the crosstalk between immune systems and peripheral tissues. In contrast to IL-10, which performs primarily regulatory functions during inflammation, IL-22 specifically upregulates the production of antimicrobial peptides, pro-inflammatory chemokines, and cytokines, and directly stimulates epithelial cell proliferation and the self-repair process (Ouyang et al. [@CR103]). IL-22 can elicit three major biological functions from various epithelial tissues: (1) antimicrobial host defense mechanisms, (2) tissue-protective effects, and (3) pro-inflammatory functions.

Epithelial Host Defense {#Sec11}
-----------------------

### IL-22 Induces the Production of Antimicrobial Peptides from Epithelial Cells {#Sec12}

To enhance innate defense, IL-22 drives the production of a broad spectrum of antimicrobial proteins from epithelial cells in tissues that are directly exposed to external pathogens. IL-22 acts on skin keratinocytes and induces S100 family proteins containing S100A7 (psoriasis), S100A8, and S100A9, and defensins including β-defensin 2 and β-defensin 3 (Liang et al. [@CR78]; Sa et al. [@CR124]; Wolk et al. [@CR163], [@CR164]). In the lung, bronchial epithelial cells preferentially produce β-defensin 2, S100A7, S100A12 (calgranulin), and lipocalin-2 upon stimulation of IL-22 (Aujla et al. [@CR4]). IL-22 can also stimulate colonic mucosal epithelium to express S100A8, S100A9, RegIIIβ, RegIIIγ, haptoglobin, SAA3, and lactotransferrin (Zheng et al. [@CR180]). Furthermore, IL-22 was reported to induce hepatic lipopolysaccharide (LPS)-binding protein (LBP) to the serum concentration known to neutralize LPS, a major outer membrane component of gram-negative bacteria (Wolk et al. [@CR165]). All these antimicrobial peptides exert essential roles in host defense (Kolls et al. [@CR70]).

### Role of IL-22 in Epithelial Defense Against Bacterial Infection {#Sec13}

It has been speculated since its discovery that IL-22 might have an important role in host defense (Aggarwal et al. [@CR1]; Dumoutier et al. [@CR34]; Wolk et al. [@CR163]). Early effort with in vivo infection of an intracellular pathogen, *Listeria monocytogenes*, indicates that IL-22 is not essential for both the innate and adaptive immunity against the infection (Zenewicz et al. [@CR176]). Because IL-22R1 is preferentially expressed on various epithelial cells and IL-22 induces the expression of many antimicrobial peptides (Sa et al. [@CR124]), we hypothesized that the major function of IL-22 may be in control of extracellular bacteria, especially on the mucosal surface. Previously we have demonstrated that IL-22 is a downstream cytokine of IL-23 that can induce the expression of IL-22 from various lymphocytes (Zheng et al. [@CR179]). A study published at the same time from Weaver's group established an indispensable role of IL-23 in host defense against *C. rodentium*, a gram-negative bacterium that infects murine colon epithelial cells and induces transient infectious colitis (Mangan et al. [@CR85]). We speculated that IL-22 could also contribute significantly in this model of mucosal infection. Indeed, IL-22 expression is augmented very quickly in the colon in an IL-23-dependent manner upon *C. rodentium* infection (Zheng et al. [@CR180]). IL-22 is both necessary and sufficient for controlling systemic bacteria dissemination and mortality during the early stage of the infection. Mice deficient in IL-22 succumb within the second week after infection. IL-22 can directly induce many antimicrobial peptides including the Reg family and S100 family of peptides from intestinal epithelial cells (IECs). The induction of Reg family peptides such as RegIIIβ and RegIIIγ by *C. rodentium* is abolished in the IL-22-deficient mice. Recombinant RegIIIγ can partially rescue the IL-22 deficient mice, suggesting RegIIIγ is one of the downstream host defense molecules induced by IL-22. Reg family peptides can directly kill *gram* ^*+*^ bacteria and induce aggregation of *gram* ^−^ bacteria (Cash et al. [@CR19]; Iovanna et al. [@CR57]).

More interestingly, in this model, ILCs, but not T cells, are the major early IL-22 producing cells in the intestine (Cella et al. [@CR20]; Satoh-Takayama et al. [@CR125]; Zheng et al. [@CR180]). T cells, however, are still required for full control of *C. rodentium* infection, because the development of the anti-*C. rodentium* IgG response that eventually clears the bacteria from colon and CD4 T cells is required for this response (Bry and Brenner [@CR17]; Maaser et al. [@CR84]). Furthermore, a second wave of IL-22 production is also detected after *C. rodentium* inoculation in mice (Basu et al. [@CR6]), which provides more complete host protection in the early stage of infection. This second wave of IL-22 is produced by Th22 cells in an IL-6-dependent, but IL-23-independent, manner.

In addition to controlling invading pathogens in the intestine, IL-22 can help to maintain the homeostasis of the mucosal barrier and commensal bacteria. A recent study shows that depletion of IL-22-producing ILCs leads to peripheral dissemination of commensal bacteria, especially *Alcaligenes* species, and systemic inflammation (Sonnenberg et al. [@CR134]). Exogenous IL-22 is able to prevent the systemic dissemination of commensal bacteria and control the inflammation. Furthermore, IL-22 controls segmented filamentous bacteria (SFB) (Ivanov et al. [@CR59]; Upadhyay et al. [@CR147]), which initiate and augment Th17 responses in the mouse small intestine. IL-22 not only reduces the amount of SFB detected in the small intestine, also regulates host defense against bacterial infections in other organs, for example, *Klebsiella pneumoniae* infection in the lung (Aujla et al. [@CR4]). In this model, IL-22 cooperates with IL-17 to induce the expression of proinflammatory cytokines and chemokines, as well as lipocalin-2, that kills *K. pneumoniae* in the lung.

In summary, IL-22 is one of the essential cytokines that regulate epithelial defense function and protect epithelial integrity. The functions of IL-22 in host defense can be categorized in several areas. First, IL-22 directly induces innate antimicrobial mechanisms via promoting the expression of bactericidal peptides. Second, IL-22 preserves the epithelial integrity and promotes the survival of epithelial cells during infection and inflammation. Third, IL-22 also augments wound-healing responses and acts on stem cells to promote recovery of the epithelial organs from damage caused by infection. Finally, IL-22 can synergize with other pro-inflammatory cytokines to induce the expression of chemokines and cytokines that recruit and activate other leukocytes.

### Potential Functions of IL-22 in Viral Infection {#Sec14}

The type III interferon (IFN) (or IFN-λ family) cytokines, IL-28A, IL-28B, and IL-29 (also called IFN-λ2, IFN-λ3, and IFN-λ1, respectively), exert important antiviral functions (Ouyang et al. [@CR103]). Interestingly, these cytokines structurally are much more closely related to IL-22 than type I IFNs. In addition, type III IFNs share the same IL-10R2 chain with IL-22 as a common receptor subunit. It is tempting, therefore, to speculate a role of IL-22 in antiviral responses. However, although type III IFNs elicit a typical IFN-stimulated gene factor 3 (ISGF3) signal pathway in antiviral response, IL-22 has not been reported to directly induce ISGF3 complex and antiviral activities in cells. It is still possible that IL-22 can enhance or synergize with IFNs during antiviral responses.

Alternatively, as IL-22 promotes tissue-protective functions, it may help to alleviate tissue damage caused by viral infection. IL-22 can also enhance antibacterial activity from the tissue and reduce the chance of secondary bacterial infections after viral invasion. Recent studies with various viral infection models support these hypotheses. In a chronic lymphocytic choriomeningitis virus (LCMV) infection model with clone 13, IL-7 limited organ pathology and damage (Pellegrini et al. [@CR110]) . One of the downstream factors induced by IL-7 in this model is IL-22, which provides an important cytoprotective function and reduces the severity of hepatitis during infection. Consistently, IL-22 is elevated in the liver during chronic hepatitis B virus infection in humans (Feng et al. [@CR40]). The increased expression of IL-22 in the liver is correlated with the grade of the inflammation and the proliferation of liver progenitor cells. Both in vitro and in vivo, IL-22 is able to promote the proliferation of liver progenitor cells, suggesting a role of IL-22 in liver protection during hepatitis B virus (HBV) infection. A similar tissue protection role of IL-22 is also observed in the lung during influenza infection (Kumar et al. [@CR75]; Paget et al. [@CR104]). IL-22-deficient mice infected with influenza develop much more severe damage of the tracheal epithelial cells than that in wild-type (WT) mice. IL-22 knockout mice also do not recover their body weight lost during the infection. In the gut, the major cellular sources of IL-22 are T cells and innate lymphoid cells. In patients with human immunodeficiency virus (HIV) infection, there is a significant reduction of IL-22-producing T helper subsets, which is correlated with compromised epithelial integrity and increased bacterial translocation (Kim et al. [@CR67]). Long-term antiretroviral therapy is able to increase IL-22-producing T cells and reverse the tissue damage in the gut. These data support an important role of IL-22 in preventing HIV-induced mucosal immunopathogenesis in the gut.

All together these data support a critical function of IL-22 in protecting various epithelial tissues from virus- and inflammation-caused destruction. Further studies are needed to investigate whether there is a direct role of IL-22 in controlling certain viral infections in epithelial cells. On the other hand, IL-22 can synergize with other cytokines to enhance inflammation under certain conditions. It has been reported that IL-22-deficient mice are more resistant to the lethal West Nile virus (WNV) encephalitis. In this model, IL-22 promotes chemokine pathways to recruit neutrophils into the central nervous system (CNS) (Wang et al. [@CR156]).

### Role of IL-22 in Yeast Infection {#Sec15}

Indispensable functional roles of Th17 and IL-17 in host defense against yeast infection have been established (Ouyang et al. [@CR102]). Patients with mutations in either IL-17 receptor or IL-17F develop chronic mucocutaneous candidiasis (CMC) (Puel et al. [@CR115]). Interestingly, in patients with CMC, their PBMCs not only produce less IL-17A but also less IL-22 upon stimulation with *Candida albicans* (Eyerich et al. [@CR38]). In addition, antibodies against IL-17A, IL-17F, and IL-22 have been observed from patients with autoimmune polyendocrine syndrome type I (APS-I)/autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) (Kisand et al. [@CR68]; Puel et al. [@CR114]). Dampened IL-22 response as well as IL-17 response is considered to associate with CMC in these patients. However, a direct causal relationship remains to be established (Zelante et al. [@CR175]).

The role of IL-22 in preclinical yeast infection has been examined in recent years. During infection of oropharyngeal candidiasis, IL-22 seems to be dispensable though Th17 and IL-17 pathways are required for host defense (Conti et al. [@CR24]). Similarly, IL-22 is not required for optimal host defense when skin is infected with *C. albicans* (Kagami et al. [@CR61]). However, IL-22 is required to prevent *C. albicans* from disseminating into stomach and kidney when the yeast is infected introgastrically (De Luca et al. [@CR27]). In this case, IL-22 induces various antimicrobial peptides such as S100A8 and RegIII-γ. Furthermore, during *Aspergillus fumigatus* infection in the lung, IL-22 is induced through a Dectin-1- and IL-23-dependent pathway and contributes to the early innate host defense in the lung (Gessner et al. [@CR42]). These data support that IL-22, similar to IL-17, participates in host defense of yeast infection.

Maintenance of Epithelial Homeostasis {#Sec16}
-------------------------------------

The antimicrobial functions elicited by IL-22 help to prevent tissue damage from invading pathogens. In addition, IL-22 directly promotes tissue protection and regeneration. First, IL-22 has anti-apoptotic functions and prevents cell damage and cell death caused by inflammation (Cella et al. [@CR20]; Radaeva et al. [@CR118]; Zenewicz et al. [@CR176]). Second, IL-22 promotes wound repair through increasing cell migration and proliferation of keratinocytes, fibroblasts, and IECs (Boniface et al. [@CR12]; Brand et al. [@CR14]; McGee et al. [@CR88]). Stat3 activation by IL-22 is essential for epithelial protection and mucosal wound healing in murine colitis triggered by chemical epithelial damage, inflammatory T cells, or bacterial infection (Pickert et al. [@CR112]; Sugimoto et al. [@CR139]; Zenewicz et al. [@CR177]; Zheng et al. [@CR180]). Third, IL-22 helps to maintain mucosal barrier functions through the restoration of a mucus layer and tight junction. Mucus-associated proteins (MUC), structural components of mucus, form a static external barrier along the epithelial cell surface and are critical for epithelial protection and the wound-healing process (Ho et al. [@CR49]; Van der Sluis et al. [@CR150]). MUC1, MUC3, MUC10 and MUC13 were upregulated from colonic epithelial cells upon IL-22 stimulation (Sugimoto et al. [@CR139]). IL-22 mediates enterocyte homeostasis and restores expression and redistribution of tight junction protein zonula occludens (OZ)-1 (Kim et al. [@CR67]; Klatt et al. [@CR69]). Finally, IL-22 is able to act on epithelial stem cells and progenitor cells and promote tissue regeneration. Given these unique functions of IL-22 in tissue protection, IL-22 may contribute to regulation of the pathogenesis in many diseases.

### Tissue-Protective Role of IL-22 in Inflammation {#Sec17}

The IL-22 receptor is expressed on many other cells with epithelial origins including hepatocytes in the liver and acinar cells in the pancreas. IL-22 plays an indispensable role in protecting these cells during inflammation. IL-22 expression is induced in liver during concanavalin A (ConA)-induced hepatitis. Blocking the IL-22 pathway by a neutralizing antibody or using IL-22-deficient mice exacerbates hepatitis as indicated by increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels (Radaeva et al. [@CR118]; Zenewicz et al. [@CR176]). Overexpression of IL-22 can protect liver from injury caused by an agonist antibody targeting Fas, ConA, or carbon tetrachloride (Pan et al. [@CR105]). In addition, treatment with exogenous IL-22 reduces alcoholic liver injury in mice receiving chronic-binge ethanol feeding (Ki et al. [@CR66]). In these models, IL-22 exerts anti-apoptotic effects, induces the expression of antioxidative products, and promotes the proliferation of the hepatocytes. More interestingly, IL-22 is also involved in liver regeneration. The expression of IL-22R on hepatocytes is increased after a partial hepatectomy in mice. Blocking the IL-22 pathway in this case reduces the proliferation of hepatocytes (Ren et al. [@CR120]). Pancreas is another organ that is targeted by IL-22. IL-22R1 is expressed at the highest level in pancreas compared to other human tissues, and acinar cells are the predominant IL-22R1^+^ cell population (Aggarwal et al. [@CR1]). Both freshly isolated murine acinar cells and a transformed cell line were able to respond to IL-22 and upregulate pancreatitis-associated protein (PAP1)/regenerating gene (Reg)2 and osteopontin (OPN). Moreover, the induction was immediately observed after in vivo IL-22 administration in an animal model. PAP/Reg proteins belong to the C-type lectin (calcium-dependent lectin) gene superfamily, which also includes RegIII genes discussed previously (Zhang et al. [@CR178]). They are not expressed in normal pancreas but are greatly elevated during pancreatic inflammation and directly stimulate β-cell proliferation, facilitate pancreatic islet regeneration, and ameliorate diabetic syndrome (Keim et al. [@CR64], [@CR65]; Orelle et al. [@CR100]; Watanabe et al. [@CR158]). A report has showed that both β-cells and α-cells may express some level of IL-22R1, but there is no direct evidence to show that they respond to IL-22 (Shioya et al. [@CR130]). In a cerulein-induced chronic pancreatitis model, exogenous IL-22 is able to reduce the release of digestive enzymes, pancreatic cell death, and inflammation, suggesting that IL-22 may have therapeutic value in this disease (Feng et al. [@CR41]).

IL-22R1 expression was found in airway epithelial cells, indicating IL-22 as a regulator in lung inflammation (Besnard et al. [@CR8]). In asthmatic patients, and patients with interstitial lung diseases such as idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), and pulmonary sarcoidosis, IL-22 expression is altered comparing to healthy lungs, suggesting IL-22 has biological function in pulmonary diseases (Whittington et al. [@CR161]). As already discussed, IL-22 is essential for maintenance of lung integrity during bacterial, fungal, and viral infection (Aujla et al. [@CR4]; Gessner et al. [@CR42]; Kumar et al. [@CR75]) and promotes both the pro-inflammatory antimicrobial responses and tissue-protective functions in the lung. Interestingly, dependent on the environmental factors, the functions of IL-22 can be beneficial or detrimental to the lung. In a bleomycin-induced lung inflammation model, IL-22 exerts a protective function when the IL-17A pathway is blocked. However, in the presence of the IL-17 pathway, IL-22 can synergize with IL-17 to amplify the inflammatory response (Sonnenberg et al. [@CR132]). On the other hand, there is evidence that IL-22 limits the Th2 inflammation in an allergic airway model (Takahashi et al. [@CR142]; Taube et al. [@CR144]), represses IL-25 production from lung epithelial cells, and reduces eosinophil infiltration in the airway (Takahashi et al. [@CR142]).

In addition to its role in promoting liver regeneration, IL-22 also facilitates the regeneration of thymus (Dudakov et al. [@CR30]). IL-22-deficient mice displayed significant delayed thymic regeneration after sublethal total body irradiation. Furthermore, IL-22 functions in maintaining intestinal stem cells (ISCs), which reside within intestinal crypts and could generate the entire crypt--villus structure (Barker et al. [@CR5]; Hanash et al. [@CR46]; Medema and Vermeulen [@CR90]; Simons and Clevers [@CR131]). In a murine graft-versus-host disease model, blocking the IL-22 pathway results in the loss of the ISCs and the increase of crypt apoptosis. Although the IL-22 receptor is not expressed on leukocytes, a role of IL-22 in retaining lymphoid structure has been revealed recently. In the murine *C. rodentium* infection model, IL-22 is downstream of the lymphoid toxin pathway. IL-22 is required for the maintenance of the isolated lymphoid follicles and colonic patches in the colon during infection (Ota et al. [@CR101]). In this case, IL-22 does not directly act on leukocytes; rather, it helps to preserve the epithelial architecture and chemokines that required for the organization of the lymphoid follicles.

### IL-22 May Be Beneficial for IBD Through Its Roles Both in Tissue Protection and Antimicrobial Functions {#Sec18}

Inflammatory bowel diseases can be classified into either ulcerative colitis (UC) or Crohn's disease (CD), both of which manifest chronic inflammation in the gastrointestinal tract. Although UC mainly affects only the colon with continuous superficial inflammation, CD involves the entire intestinal track with patchy, sometimes transmural inflammation. Both environmental factors and genetic predispositions contribute to the pathogenesis of the IBD, although the exact triggers of the disease remain unclear. Recent genome-wide association studies (GWAS) in IBD and data from preclinical animal models suggest that maintenance of the homeostasis of the intestinal microflora and mucosal epithelial barrier may be important.

The IL-22 pathway is not linked with IBD in GWAS analysis, but significantly increased expression of IL-22 is reported in inflamed intestinal mucosa biopsies from IBD patients, and the level of IL-22 is correlated with disease severity (Andoh et al. [@CR3]; Brand et al. [@CR14]; Schmechel et al. [@CR129]). As discussed, IL-23 is an essential upstream cytokine that induces the expression of IL-22 in the intestine. Both IL-23R and IL-12/IL-23p40 subunit are associated with IBD genetically. Interestingly, there is a correlation between serum IL-22 levels and IL-23R minor alleles in CD, in which lower IL-22 expression is linked with protective single nucleotide polymorphisms (SNPs) of IL-23 (Schmechel et al. [@CR129]). As discussed previously, IL-22 effectively induces or synergizes the secretion of pro-inflammatory cytokines and chemokines (IL-6, IL-8, IL-11, leukemia inhibitory factor), pro-angiogenic mediators (MMP-1, MMP-3, MMP-10), growth factor (amphiregulin), and immune suppressor (IL-10, SOCS3) in colon (Andoh et al. [@CR3]; Brand et al. [@CR14]; Nagalakshmi et al. [@CR94]). IL-22 facilitates IFN-γ for inducible nitric oxide synthase (iNOS) production in human colon carcinoma cells, and iNOS is associated with inflammation and immune activation (Ziesche et al. [@CR181]).

IL-22 is upregulated and has a beneficial role in several preclinical colitis models (Neufert et al. [@CR98]; Pickert et al. [@CR112]; Sugimoto et al. [@CR139]; Zenewicz et al. [@CR177]). Although IL-22 does not directly repress inflammatory responses, it may help to dampen the symptoms in IBD in several ways (Fig. [6.4](#Fig4){ref-type="fig"}). First, IL-22 induces the production of antimicrobial peptides, such as Reg family of C-type letins, defensins, and cathelicidins, from intestinal epithelial cells and Paneth cells (Pickert et al. [@CR112]; Sugimoto et al. [@CR139]; Zenewicz et al. [@CR177]; Zheng et al. [@CR180]). Second, IL-22 preserves the integrity of the mucosal epithelial layers. IL-22 not only may reduce epithelial apoptosis but also helps to retain the tight junctions in epithelial cells during infection and inflammation (Cella et al. [@CR20]; Kim et al. [@CR67]). IL-22 also promotes epithelial proliferation and triggers wound-healing responses (Brand et al. [@CR14]; Neufert et al. [@CR98]; Pickert et al. [@CR112]). In addition, IL-22 can direct act on intestinal epithelial stem cells and enhance the regeneration (Hanash et al. [@CR46]). Third, IL-22 augments the production of MUC proteins, which can sequester luminal flora from directly interacting with epithelial cells (Sugimoto et al. [@CR139]). Finally, IL-22 stimulates chemokine production from epithelial cells to boost leukocyte infiltration. Fig. 6.4IL-22 protects intestinal epithelia in inflammatory bowel disease (IBD). IL-22 restores epithelial integrity through four major biological functions: promoting antimicrobial peptide secretion from epithelial cells; directly stimulating epithelial cell survival, proliferation, migration, and regeneration; increasing the production of mucous proteins by goblet cells, and triggering leukocyte infiltration via activating the chemokine production from epithelial cells

Based on its functions, IL-22 may offer certain therapeutic value in IBD, especially when epithelial damage and changes of luminal flora are major triggers of intestinal inflammation. As IL-22 does not suppress inflammation directly, additional anti-inflammatory treatments may be needed to cooperate with the effects of IL-22. In fact, IL-22 by itself can exacerbate intestinal inflammation under certain conditions. In colitis induced by transferring CD45Rb^low^ CD4^+^ memory cells that are deficient in IL-10 pathway, IL-22 amplifies the intestinal inflammation (Kamanaka et al. [@CR63]). A similar pathogenic role of IL-22 is again revealed in a small intestinal inflammation model triggered by infection with *Toxoplasma gondii* (Munoz et al. [@CR91]).

### Role of IL-22 in Oncogenesis {#Sec19}

Stat3 is a known oncogene and has an important role in many different types of cancer (Hodge et al. [@CR50]). Cytokines, such as IL-6, that activate Stat3, have been connected with tumorigenesis under chronic inflammatory conditions (Naugler et al. [@CR97]). Because IL-22 directly targets epithelial cells and induces Stat3 activation, it is possible that IL-22 may promote certain epithelial-derived tumors. Under homeostatic states, IL-22 can induce epithelial proliferation and elicit wound-healing responses. However, its pro-proliferative activity is in general much weaker than that of some of the other epithelial growth factors such as EGF and KGF (Sa et al. [@CR124]).

Earlier study with IL-22 overexpressed in a murine carcinoma cell line, colon 26 cells, demonstrated that the growth and metastasis of the tumor in syngeneic mice is not different from the control parental cells (Nagakawa et al. [@CR93]). The survival of the mice that are intraperitoneally inoculated with IL-22-expressing colon 26 cells is significantly prolonged. The reason of this extended survival of the mice is unclear.

The first important information regarding a potential role of IL-22 in tumorigenesis comes from the study with IL-22 transgenic mice. Gao and colleagues generated an IL-22 transgenic (Tg) mouse strain in which IL-22 is under the control of a albumin promoter (Park et al. [@CR108]). Although IL-22 is specifically expressed in the liver, IL-22 is readily detectable in the serum. Different from the previous IL-22 Tg mice that die prenatally, these albumin-driven IL-22 Tg mice developed normally and survived more than 2 years. In these mice, the authors did not find any spontaneously developed tumors. Interestingly, IL-22 Tg mice are more susceptible to diethylnitrosamine, a liver carcinogen that induces hepatocarcinoma, supporting a role of IL-22 in promoting the growth of existing cancers. IL-22 is overexpressed in adipose tissue under the control of aP2 promoter in a Tg line (Wang et al. [@CR155]). Although no obvious metabolic phenotypes are observed in these Tg mice, all Tg mice developed spontaneous liposarcomas after feeding with a high-fat diet (HFD). Interestingly, none of the wild-type (WT) mice fed with HFD or IL-22 Tg mice fed with a normal diet develop similar tumors. In both cases, it is unclear what the local IL-22 concentration is in the targeted tissue, which may be significantly higher than normal endogenous level of IL-22.

The potential role of physiological IL-22 level in tumorigenesis has been recently examined in colon cancer models using IL-22, IL-22BP knockout mice, and IL-22 neutralizing antibody (Huber et al. [@CR51]). In the carcinogen-induced, colitis-associated colon cancer model, IL-22BP knockout mice have increased tumor burden, which is dependent on IL-22. Similar results are also observed in the APC^min/+^ model of colon cancer. These data again support a role of IL-22 in promoting existing colon cancer. On the other hand, the development of colon cancer is associated with colitis, and IL-22 can alleviate colitis in preclinical models. IL-22 may prevent the initiation of colon cancer by repression of colitis. Indeed, anti-IL-22 treatment can increase tumor burden if treated early in the model, supporting a protective role of IL-22 in colon tumorigenesis at the early stage.

Although IL-22 promotes the existing colon tumors at the late stage, the long-term outcome of these tumors has not been examined. Stat3 was reported to have a dual role in the development of colon cancer in APC^min/+^ mice carrying IEC-specific deletion of Stat3 (Musteanu et al. [@CR92]). In the absence of Stat3, the number of intestinal epithelial adenoma is reduced at an early stage, suggesting the Stat3 pathway may play a role in promoting tumor growth. Interesting, at the later stage, there is significantly increased tumor burden in both small intestine and colon without Stat3. Loss of Stat3 not only enhances the tumor progression and invasiveness but also significantly reduces the survival of APC^min/+^ mice. Together, the data suggest that activated Stat3 may help control the progression of intestinal cancers. It is unclear whether there is a similar role of IL-22, given its function in activation of Stat3.

Inflammation and Autoimmune Diseases {#Sec20}
------------------------------------

Similar to many other cytokines including IL-6, TNF-α, and IL-1β, IL-22 is able to promote inflammatory responses. Three major functions of IL-22 contribute to the inflammatory cascade. First, many of the antimicrobial peptides such as S100 family proteins, induced by IL-22, can recruit and activate leukocytes. Second, IL-22 stimulates the expression of a large group of chemokines from epithelial cells. Third, IL-22 can directly act on liver and other organs to trigger the release of acute-phase proteins, whose plasma concentration changes in response to inflammation to restrain infection, damp local inflammation, and rebuild tissue homeostasis (Baumann and Gauldie [@CR7]; Steel and Whitehead [@CR137]). As discussed earlier, however, despite these pro-inflammatory effects, the net functional outcome of IL-22 in inflammation and infection could be an alleviated inflammatory response (Radaeva et al. [@CR118]; Sugimoto et al. [@CR139]; Zenewicz et al. [@CR176], [@CR177]; Zheng et al. [@CR180]). Under other conditions, IL-22 elicits strong pro-inflammatory effects and contributes to the pathogenesis of many inflammatory diseases (Kamanaka et al. [@CR63]; Munoz et al. [@CR91]; Zheng et al. [@CR179]). These contradictory effects of IL-22 are likely caused by the shifted balance between the tissue-protective effects and pro-inflammatory functions of IL-22. Thus, pro-inflammatory functions of IL-22 are largely dictated by the context of tissue microenvironment, type of infection, or other pro-inflammatory mediators.

### IL-22 Induces Expression of Chemokines and Triggers Acute-Phase Reaction {#Sec21}

Despite the minimal effect of IL-22 on cytokine secretion, IL-22 strongly upregulates many chemokines in various organs and contributes to immune regulation by recruiting leukocyte infiltration. IL-22 directly upregulates CXCL10 (IP-10), CCL2 (MCP-1), IL-8, and CXCL1 in hepatocytes, resulting in the recruitment of monocytes, effector T cells, NK cells, and neutrophils (Donnelly et al. [@CR29]; Liang et al. [@CR79]). Similarly, chemoattractants IL-8, CXCL1, CXCL2 (MIP2-a), CXCL3 (MIP2-b), CXCL6, and CCL7 were positively regulated by IL-22 in human colonic subepithelial myofibroblasts and were elevated in inflamed colonic lesions of IBD patients (Andoh et al. [@CR3]; Brand et al. [@CR14]). There was an even greater variety of chemokines induced by IL-22 in human keratinocytes including IL-8, CXCL1, CXCL7, CXCL9 (MIG), CXCL10, CXCL11 (I-TAC), CCL2, CCL5 (RANTES), CCL20 (MIP3-a), and CCL26 (Eotaxin-3). All these chemokines not only activate chemotaxis in various leukocyte populations (monocytes, macrophages, dendritic cells, activated T cells, eosinophils, basophils, and neutrophils), but also stimulate other processes such as mitogenesis, synthesis of extracellular matrix, glucose metabolism, and phagocytosis (Eyerich et al. [@CR39]; Sa et al. [@CR124]). Similar observations were found in pulmonary diseases and rheumatoid arthritis (RA) (Aujla et al. [@CR4]; Besnard et al. [@CR8]; Ikeuchi et al. [@CR56]). In preclinical studies, the infiltration of leukocytes into inflammation sites was significantly reduced in IL-22-deficient animals or those treated with IL-22-neutralizing antibody.

The liver is the predominant organ of pro-inflammatory response. IL-22 was initially characterized as a hepatocyte-stimulating factor for its ability to upregulate acute-phase proteins, such as serum amyloid A (SAA), a1-antichymotrypsin, and haptoglobin in several hepatoma cell lines (Dumoutier et al. [@CR34]). In addition, the production of both fibrinogen and LBP by hepatocytes was enhanced after IL-22 administration (Liang et al. [@CR79]; Wolk et al. [@CR165]). With sustained exposure to IL-22 delivered by the adenoviral system or liver-specific transgene expression, circulating blood cells were altered with increased blood platelets and decreased red blood cells. Furthermore, body weight loss, thymic atrophy, and renal proximal tubule metabolic activity associated with acute inflammation were also detected (Liang et al. [@CR79]). Besides acting on the vital organs, IL-22 is expressed in RA synovial tissues and mononuclear cells in synovial fluid, and contributes to joint inflammation primarily through directly promoting fibroblast proliferation and monocyte chemoattractant protein 1 (MCP-1) (Ikeuchi et al. [@CR56]).

### Pathogenic Role of IL-22 in Psoriasis {#Sec22}

The possible link between IL-22 and psoriasis was first revealed by studying the closely related family member IL-20 (Blumberg et al. [@CR11]). Overexpressing IL-20 in Tg mice results in abnormal skin phenotypes, including wrinkled and shiny skin with a thickened epidermis. Histological analysis further identifies epidermal hyperplasia and compact stratum corneum, consistent with some of the histological features observed in psoriatic skin, in these mice. Interestingly, similar phenotypes are also observed in IL-22 and IL-24 Tg mice, suggesting common biological functions of this group of cytokines in the skin (He and Liang [@CR48]; Wolk et al. [@CR166]). IL-22 receptors are highly expressed by keratinocytes (Sa et al. [@CR124]). Detailed in vitro studies with human primary epidermis demonstrate that IL-22 as well as other family members including IL-19, IL-20, and IL-24 can directly induce many downstream biological features observed in psoriatic skin. For example, IL-22 activates p-STAT3 in human keratinocytes and induces the expression of several pro-inflammatory proteins including members of S100 family of calcium-binding proteins, β-defensins, and matrix metalloproteinases (MMP) (Boniface et al. [@CR12]; Ma et al. [@CR83]; Sa et al. [@CR124]; Wolk et al. [@CR163]). Specifically, S100A7, S100A8, and S100A9 are produced promptly when normal human epidermal keratinocytes are treated with IL-22, and they function as chemoattractants of innate immune cells (Roth et al. [@CR121]; Watson et al. [@CR159]). β-Defensin 2 and -3 are induced by IL-22 in human primary keratinocytes, and contribute to inflammation through activation and degranulation of mast cells and CCR6-mediated chemotaxis for immature DCs and CD4 memory T cells (Niyonsaba et al. [@CR99]; Yang et al. [@CR171]). MMPs, also called matrixins, have an essential role in cell mobility and tissue remodeling (Nagase and Woessner [@CR95]). In addition, IL-22 promotes epidermal keratinocyte proliferation and abnormal differentiation similar to those observed in psoriatic skin. Among all its family members, IL-22 appears to be the most potent in induction of these biological effects from keratinocytes (Sa et al. [@CR124]).

In humans, elevated IL-22 has been detected in lesional skin and serum from psoriasis patients (Boniface et al. [@CR12], [@CR13]; Kagami et al. [@CR62]; Pene et al. [@CR111]; Wolk et al. [@CR163]). In addition, IL-22-producing T helper subsets, including Th17 and Th22 cells, have been isolated from psoriatic skin. Th17 cells produce both IL-22 and IL-17. IL-17 also exerts essential pathogenic functions in psoriasis. It induces many similar genes as those by IL-22 from keratinocytes (Liang et al. [@CR78]; Tohyama et al. [@CR145]). Blocking the IL-17 pathway ameliorates skin inflammation in many preclinical psoriatic models (van der Fits et al. [@CR149]). More importantly, in clinic, blocking the antibody targeting IL-17 or the IL-17 receptor results in very impressive efficacy in treatment of psoriasis (Hueber et al. [@CR52]; Leonardi et al. [@CR77]; Papp et al. [@CR106]). IL-22 is able to synergize with IL-17 and amplify inflammatory responses in the skin.

Human genetic studies in psoriasis also support an important role of IL-22 in the pathogenesis. Both IL-12/IL-23 p40 subunit and IL-23 receptor have been linked to psoriasis in GWAS (Capon et al. [@CR18]). A protective SNP identified in IL-23R leads to reduced IL-23R expression and decreased IL-22 production upon IL-23 stimulation in T cells (Pidasheva et al. [@CR113]). IL-23 has important functions in Th17 cell development in vivo (McGeachy and Cua [@CR87]) and is indispensable for IL-22 induction from both T cells and ILCs (Ouyang et al. [@CR103]). In clinic, the antibody-neutralizing IL-12/IL-23 p40 subunit succeeds in treatment of psoriasis (Krueger et al. [@CR74]). The efficacy of anti-IL-23 could result partly from the block of IL-22 induction by IL-23. Indeed, in a preclinical mouse model, IL-23 is able to directly induce skin inflammation and acanthosis, and these phenotypes are alleviated in IL-22-deficient mice (Zheng et al. [@CR179]). Blocking IL-22 is efficacious in several other preclinical models of skin inflammation (Ma et al. [@CR83]; Van Belle et al. [@CR148]).

Another protein, Act1, is identified to associate with psoriasis by three independent GWAS (Ellinghaus et al. [@CR37]; Huffmeier et al. [@CR53]; Strange et al. [@CR138]). Act1 is an important adaptor molecule recruited to the receptor of IL-17 and is essential for the function of IL-17 (Chang et al. [@CR21]; Qian et al. [@CR116]). The variant of Act1 identified in psoriasis replaces asparagine for the aspartic acid at the position 10. This loss-of-function mutation results in abolished IL-17-dependent functions. Given an important pathogenic function of IL-17 as already discussed, it is paradoxical that this Act1 mutation is associated with increased risk of development of psoriasis. A recent study, however, revealed that in the mouse this mutation leads to a significantly increased production of IL-22 from T cells (Wang et al. [@CR157]). In addition, these mice spontaneously develop skin inflammation that can be blocked by IL-22-neutralizing antibody.

Taken together, these data support an important role of IL-22 in the pathogenesis of psoriasis. However, it is unclear whether blocking IL-22 by itself will provide sufficient therapeutic benefit in psoriasis. First, several other IL-10 family members, IL-19, IL-20, and IL-24 are also elevated in human psoriatic skin and can induce similar downstream biological effects in the skin. Second, although IL-22 induces many unique patterns and genes from keratinocytes in psoriasis, it is a relative weak cytokine in promoting inflammatory responses in comparison with other cytokines such as IL-17 and TNF-α. IL-22 usually synergizes with these cytokines to further amplify inflammation. Further clinical studies may be necessary to fully assess the role of IL-22 in psoriasis.
